Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | PDE5A | O76074 | 17/20 | 0.76 |
| ▸ | PDE6C | P51160 | 3/20 | 0.76 |
| ▸ | PDE1A | P54750 | 3/20 | 0.76 |
| ▸ | PDE2A | O00408 | 2/20 | 0.76 |
| ▸ | PDE9A | O76083 | 2/20 | 0.76 |
| ▸ | PDE4A | P27815 | 2/20 | 0.76 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.76 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.76 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.76 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.76 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.76 |
| ▸ | PDE6D | O43924 | 1/20 | 0.76 |
| ▸ | PDE8A | O60658 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655374 | 1.00 | KMT2A (0.83) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL31202676 | 0.94 | KMT2A (0.73) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL1253 | 0.94 | KMT2A (0.73) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL6628860 | 0.92 | KMT2A (0.85) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL3313876 | 0.92 | KMT2A (0.70) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL21995693 | 0.91 | KMT2A (0.83) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL5450370 | 0.90 | KMT2A (0.71) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL1263 | 0.90 | KMT2A (0.68) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL30848678 | 0.89 | PDE5A (0.95) | KMT2AKDM4EPDE5APDE6CPDE1A | |
| SCHEMBL845 | 0.88 | PDE5A (0.68) | KMT2AKDM4EPDE5APDE6CPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | claimed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | claimed |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-03-09 | — | — | US | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| EP-4605088-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024086361-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4259634-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| WO-1999064033-A9 | PHOSPHODIESTERASE-V MODULATOR DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | KMT2A 2669/4885KDM4E 170/4885PDE5A 1/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | KMT2A 1830/4885KDM4E 883/4885PDE5A 1/4885 |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | KMT2A 2669/4885KDM4E 170/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.